Which medications in the drug class CAR T-Cell Therapies are used in the treatment of Multiple Myeloma?

Updated: May 11, 2021
  • Author: Dhaval Shah, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print

CAR T-Cell Therapies

Idecabtagene vicleucel (Abecma)

B-cell maturation antigen (BCMA)-directed genetically modified autologous CAR T-cell therapy is indicated for relapsed or refractory MM after ≥4 prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. Each idecabtagene vicleucel dose is customized using a patient’s own T-cells to help fight the myeloma. These T-cells are collected and genetically modified to include a new gene that facilitates targeting and killing myeloma cells. Once modified, the cells are infused back into the patient. 

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!